Jefferies Group Weighs in on Collegium Pharmaceutical, Inc.’s FY2021 Earnings (COLL)
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities research analysts at Jefferies Group cut their FY2021 earnings estimates for Collegium Pharmaceutical in a report released on Tuesday. Jefferies Group analyst D. Steinberg now expects that the specialty pharmaceutical company will post earnings per share of $1.36 for the year, down from their previous forecast of $1.50. Jefferies Group has a “Buy” rating and a $27.00 price target on the stock.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. During the same quarter last year, the company posted ($1.13) earnings per share. The company’s revenue for the quarter was up 2814.6% compared to the same quarter last year.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded down $0.64 during mid-day trading on Wednesday, reaching $17.70. The company’s stock had a trading volume of 1,342,032 shares, compared to its average volume of 515,147. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92.
In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the sale, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Alison B. Fleming sold 4,029 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the sale, the chief technology officer now directly owns 28,513 shares of the company’s stock, valued at $484,721. The disclosure for this sale can be found here. In the last quarter, insiders have sold 58,630 shares of company stock worth $924,360. Corporate insiders own 25.76% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Pura Vida Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $1,229,000. Wells Fargo & Company MN boosted its position in shares of Collegium Pharmaceutical by 12.8% in the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after acquiring an additional 5,136 shares during the period. Citadel Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 773.8% in the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after acquiring an additional 481,771 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $201,000. 79.98% of the stock is owned by institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.